Description
The RUU-PL7F12 monoclonal antibody specifically recognizes CD61, a 110 kDa type I transmembrane glycoprotein, also known as Glycoprotein IIIa (gpIIIa), the common β-subunit (integrin β3-chain) of the gpIIb/IIIa complex and the vitronectin receptor (VNR). The gpIIb/IIIa complex and the VNR are integrins, ie, α/β-heterodimeric glycoprotein complexes that are involved in cell adhesion. With the CD41 antigen (gpIIb or αIIb), the CD61 antigen forms the gpIIb/IIIa complex, which acts as a receptor for fibrinogen, von Willebrand factor (vWf), fibronectin, and vitronectin on activated platelets. With the CD51 antigen (VNR α-chain or αv), the CD61 antigen forms the VNR, which mediates activation-independent cell adhesion to vitronectin, vWf, fibrinogen, and thrombospondin. The CD61 antigen is found on all normal resting and activated platelets. Platelets from individuals with Glanzmann's thrombasthenia show a >90% reduction of binding of CD61, and heterozygote carriers of the disorder show approximately 50% reduction. The CD61 antigen is also found on endothelial cells, megakaryocytes, and on some myeloid, erythroid, and T-lymphoid leukemic cell lines.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Researchers should determine the optimal concentration of this reagent for their individual applications.
2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
4. An isotype control should be used at the same concentration as the antibody of interest.
5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
6. CF™ is a trademark of Biotium, Inc.
7. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
